REPL Share Price Performance
US$4.35
-6.19 (-58.73%)
Price US$4.35
Share PriceUS$4.35
Replimune Group, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
REPL Community Narratives
There are no narratives available yet.
Recent REPL News & Updates
Replimune Group, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.59
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 13.9%
Replimune Group, Inc. Competitors
Snowflake Analysis
About REPL
- Founded
- 2015
- Employees
- 479
- CEO
- WebsiteView website
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: -1.3%
- 3 Months: 7.3%
- 1 Year: 14.4%
- Year to Date: 13.5%
Over the last 7 days, the market has dropped 1.3%, driven by a pullback of 2.1% in the Financials sector. As for the longer term, the market has actually risen by 14% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›